Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Frontiers in Oncology|April 4, 2022
Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE PlatformFabio Efficace, Andrea Patriarca, Mario Luppi, et al.
International Journal of Cardiology|November 13, 2019
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitorsGiovanni Caocci, Olga Mulas, Mario Annunziata, et al.
Cancer|April 1, 2022
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosisFrancesca Palandri, Daniela Bartoletti, Alessandra Iurlo, et al.
Annals of Hematology|January 3, 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinibGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
Cancer|December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapyFrancesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Cancers|October 28, 2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with MyelofibrosisFrancesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
Annals of Hematology|January 21, 2026
Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational studyAnna Paola Iori, Antonio De Vivo, Eros Di Bona, et al.
Cancers|July 29, 2023
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET StudyFrancesca Palandri, Elena Rossi, Giuseppe Auteri, et al.
Annals of Hematology|June 1, 2020
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitorsOlga Mulas, Giovanni Caocci, Fabio Stagno, et al.
Cancer|July 30, 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.
Pageof 15